CHMP vurderede, at moxifloxacin ikke kan anvendes til PID i empirisk monoterapi på grund af den stigende incidens af fluoroquinolon- resistente N. gonorrhoeae, medmindre man kan udelukke en resistent stamme.
The CHMP considered that moxifloxacin cannot be used in the setting of PID in empirical monotherapy due to the increasing incidence of fluoroquinolone-resistant N. gonorrhoeae, unless a resistant strain can be excluded.